

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		To be assigned	
				FILING DATE		Concurrently herewith	
				APPLICANT		Michael Tolar MARTIN	
				GROUP		To be assigned	
				EXAMINER		To be assigned	
				ATTORNEY DOCKET NO.		PU4975USW	

U.S. PATENT DOCUMENTS							
Examiner Initials	Serial No.	Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
N	1.	3,828,078	08/06/1974	MROZIK			
Continue on page _____							

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Serial No.	Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
JP	2.	WO 01/17982	03/15/2001	PCT			
Continue on page _____							

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)	
JP 3.	Balzarini, "Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy," <i>Biochemical Pharmacology</i> 58(1):1-27 (Jun. 1999).
JP 4.	De Clercq, "Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection," <i>Il Farmaco</i> 54:26-45 (1999).
Continue on page _____	

EXAMINER	DATE CONSIDERED
a. Paul	9/16/02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.